PMGC Holdings Subsidiary Finalizes Exclusive IP License for Animal Health Applications
ELAB is trading near its 52-week low of $1.52 (12% above the low) on light trading volume (0.2× avg).
Summary
PMGC Holdings Inc.'s subsidiary, Northstrive Biosciences Inc., entered into a definitive exclusive, royalty-bearing license agreement with Modulant Biosciences LLC for its intellectual property in non-human animal health.
Key Events · M&A and Partnerships · ELAB
-
Definitive License Agreement Executed
Northstrive Biosciences Inc., a wholly-owned subsidiary, finalized an exclusive, royalty-bearing, sublicensable license agreement with Modulant Biosciences LLC, formalizing a binding term sheet previously reported on May 16, 2025.
-
Focus on Non-Human Animal Health
The license grants Modulant rights to develop, manufacture, and commercialize Licensed Products solely in the field of non-human animal health, including feed additive applications, worldwide (excluding the Republic of Korea).
-
Revenue Sharing Model
Modulant will pay Northstrive Biosciences a percentage of all IP Revenue, with a higher rate until a certain aggregate threshold amount is met, then a lower rate thereafter. Specific percentages and the threshold amount are redacted.
-
Commitment to Commercialization
Modulant is obligated to use 'Commercially Reasonable Efforts' to develop and commercialize at least one Licensed Product in the specified field and territory.
Analysis · ELAB · Life Sciences
PMGC Holdings Inc.'s subsidiary, Northstrive Biosciences Inc., has finalized a definitive, exclusive, royalty-bearing license agreement with Modulant Biosciences LLC for its intellectual property related to myostatin and Activin-A for non-human animal health applications. This agreement formalizes the terms of a binding term sheet previously reported on May 16, 2025. For a life sciences company like PMGC Holdings, securing a definitive licensing agreement is a crucial step towards commercializing its intellectual property and establishing a long-term revenue stream, even if the specific financial terms (revenue share percentages and threshold amount) are redacted. This development follows a period of significant capital raises and an acquisition, indicating the company's active efforts to grow and monetize its assets.
At the time of this filing, ELAB was trading at $1.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $1.52 to $185.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.